Ann: March 2024 Quarterly Activities Report & Appendix 4C, page-65

iol playez - tighter and tighter on that anchor chain

you're right I am ignorant on a great many issues

however i can assure you an in house product TPM is a shrewd move in the regulatory approval and commercialisation of CBD+TPM into the vacant S3 pharmaceutical space other than Epidiolex

in house development of TPM has:
- removed the need for licensing and procurement contracts of a partner product
- removes the need to renegotiate those costs across global juristictions as the product is distributed
- removes the requirement to review those contracts annually
- allows AVE to consolidate spending and negotiate the the licensing of TPM globally upon regulatory approval
- removes additional costs to AVE evaluating product lifecycle in an outsourced product

these of course are all cost and additional spend saves to AVE in the trial for CBD+TPM and will in fact if successful generate significant revenue = $$$$

just to mention a few lol
the list goes on matey but I suspect its of no use to you at that depth really is it

on this basis I'm happy to remain ignorant